Kane Biotech Inc. (TSXV:KNE)

Kane Biotech Statistics

Total Valuation

Kane Biotech has a market cap or net worth of CAD 8.17 million. The enterprise value is 9.53 million.

Market Cap	8.17M
Enterprise Value	9.53M

Important Dates

The next estimated earnings date is Tuesday, April 28, 2026.

Earnings Date	Apr 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Kane Biotech has 181.60 million shares outstanding. The number of shares has increased by 34.53% in one year.

Current Share Class	181.60M
Shares Outstanding	181.60M
Shares Change (YoY)	+34.53%
Shares Change (QoQ)	+87.89%
Owned by Insiders (%)	44.09%
Owned by Institutions (%)	n/a
Float	101.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.22
PB Ratio	-10.30
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.93
EV / Sales	16.58
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.17

Financial Position

The company has a current ratio of 0.90

Current Ratio	0.90
Quick Ratio	0.58
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.76
Interest Coverage	-9.70

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-52.58%
Return on Invested Capital (ROIC)	-112.51%
Return on Capital Employed (ROCE)	-316.77%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.17
Inventory Turnover	1.30

Taxes

Income Tax	-1.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.00% in the last 52 weeks. The beta is 0.18, so Kane Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.18
52-Week Price Change	-55.00%
50-Day Moving Average	0.03
200-Day Moving Average	0.05
Relative Strength Index (RSI)	61.30
Average Volume (20 Days)	224,386

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kane Biotech had revenue of CAD 574,867 and -3.26 million in losses. Loss per share was -0.02.

Revenue	574,867
Gross Profit	-95,412
Operating Income	-2.80M
Pretax Income	-3.26M
Net Income	-3.26M
EBITDA	-2.72M
EBIT	-2.80M
Loss Per Share	-0.02

Balance Sheet

The company has 939,062 in cash and 2.30 million in debt, with a net cash position of -1.36 million or -0.01 per share.

Cash & Cash Equivalents	939,062
Total Debt	2.30M
Net Cash	-1.36M
Net Cash Per Share	-0.01
Equity (Book Value)	-793,369
Book Value Per Share	-0.00
Working Capital	-186,489

Cash Flow

In the last 12 months, operating cash flow was -2.99 million and capital expenditures -9,385, giving a free cash flow of -3.00 million.

Operating Cash Flow	-2.99M
Capital Expenditures	-9,385
Free Cash Flow	-3.00M
FCF Per Share	-0.02

Margins

Gross Margin	-16.60%
Operating Margin	-486.26%
Pretax Margin	-566.62%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kane Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-34.53%
Shareholder Yield	-34.53%
Earnings Yield	-39.86%
FCF Yield	-36.76%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on March 13, 2017. It was a reverse split with a ratio of 0.2.

Last Split Date	Mar 13, 2017
Split Type	Reverse
Split Ratio	0.2

Scores

Kane Biotech has an Altman Z-Score of -19.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-19.8
Piotroski F-Score	2